Search Results
Graduate Program in Microbiology, Immunology, and Cancer Biology, University of Minnesota, Minneapolis, Minnesota, USA
Search for other papers by Mark Daniel in
Google Scholar
PubMed
Search for other papers by Todd P Knutson in
Google Scholar
PubMed
Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA
Search for other papers by Jamie M Sperger in
Google Scholar
PubMed
Search for other papers by Yingming Li in
Google Scholar
PubMed
Search for other papers by Anupama Singh in
Google Scholar
PubMed
Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA
Search for other papers by Charlotte N Stahlfeld in
Google Scholar
PubMed
Search for other papers by Courtney Passow in
Google Scholar
PubMed
Search for other papers by Benjamin Auch in
Google Scholar
PubMed
Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA
Search for other papers by Joshua M Lang in
Google Scholar
PubMed
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA
Department of Urology, University of Minnesota, Minneapolis, Minnesota, USA
Search for other papers by Scott M Dehm in
Google Scholar
PubMed
are challenging and a high burden for patients. As a result, assessing CRPC genomic alterations via blood-based 'liquid biopsy' is an attractive alternative. One common liquid biopsy approach involves the examination of circulating tumor cells (CTCs
Search for other papers by Walid Zeyghami in
Google Scholar
PubMed
Search for other papers by Marie-Louise Uhre Hansen in
Google Scholar
PubMed
Search for other papers by Kathrine Kronberg Jakobsen in
Google Scholar
PubMed
Search for other papers by Christian Groenhøj in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Clinical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Clinical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Christian von Buchwald in
Google Scholar
PubMed
Search for other papers by Christoffer Holst Hahn in
Google Scholar
PubMed
for MTC ( Van Veelen et al. 2009 ). Liquid biopsy has been suggested as a new and noninvasive way to diagnose cancer, monitor treatment response, and aid in cancer surveillance ( Payne et al. 2018 ). Liquid biopsies consist of isolating entities
Search for other papers by Karel Pacak in
Google Scholar
PubMed
Search for other papers by Mark Kidd in
Google Scholar
PubMed
Search for other papers by Leah Meuter in
Google Scholar
PubMed
Search for other papers by Irvin M Modlin in
Google Scholar
PubMed
. A liquid biopsy approach (e.g. using blood as opposed to tissue) has diagnostic value and can, in addition, provide relevant biological information in respect of the presence of a tumor and its behavior. The NETest is a multigenomic mRNA liquid
Search for other papers by Ophélie Delcorte in
Google Scholar
PubMed
Search for other papers by Julie Craps in
Google Scholar
PubMed
Search for other papers by Siam Mahibullah in
Google Scholar
PubMed
Search for other papers by Catherine Spourquet in
Google Scholar
PubMed
Search for other papers by Ludovic D’Auria in
Google Scholar
PubMed
Search for other papers by Patrick Van Der Smissen in
Google Scholar
PubMed
Search for other papers by Chantal Dessy in
Google Scholar
PubMed
Search for other papers by Etienne Marbaix in
Google Scholar
PubMed
Search for other papers by Michel Mourad in
Google Scholar
PubMed
Search for other papers by Christophe E Pierreux in
Google Scholar
PubMed
reduce overtreatment, the discovery and the development of more accurate diagnostic tools are a necessity ( Oblak et al. 2021 ). Recently, liquid biopsy has emerged as a promising opportunity to develop non-invasive and sensitive biomarkers for
Search for other papers by Alexa Childs in
Google Scholar
PubMed
Search for other papers by Christopher D Steele in
Google Scholar
PubMed
Search for other papers by Clare Vesely in
Google Scholar
PubMed
Search for other papers by Francesca M Rizzo in
Google Scholar
PubMed
Search for other papers by Leah Ensell in
Google Scholar
PubMed
Search for other papers by Helen Lowe in
Google Scholar
PubMed
Search for other papers by Pawan Dhami in
Google Scholar
PubMed
Search for other papers by Heli Vaikkinen in
Google Scholar
PubMed
Search for other papers by Tu Vinh Luong in
Google Scholar
PubMed
Search for other papers by Lucia Conde in
Google Scholar
PubMed
Search for other papers by Javier Herrero in
Google Scholar
PubMed
Search for other papers by Martyn Caplin in
Google Scholar
PubMed
Search for other papers by Christos Toumpanakis in
Google Scholar
PubMed
Department of Oncology, Royal Free London NHS Foundation Trust, London, UK
Search for other papers by Christina Thirlwell in
Google Scholar
PubMed
Search for other papers by John A Hartley in
Google Scholar
PubMed
Department of Cellular and Molecular Pathology, Royal National Orthopaedic Hospital NHS Trust, Stanmore, Middlesex, UK
Search for other papers by Nischalan Pillay in
Google Scholar
PubMed
Department of Oncology, Royal Free London NHS Foundation Trust, London, UK
Search for other papers by Tim Meyer in
Google Scholar
PubMed
. Furthermore, characterization of single-circulating tumor cells (CTCs) as part of a minimally invasive 'liquid biopsy' provides an opportunity to explore tumor biology and identify therapeutic targets. The first clinical applications of CTCs focused on
Search for other papers by Masaki Shiota in
Google Scholar
PubMed
Search for other papers by Shusuke Akamatsu in
Google Scholar
PubMed
Search for other papers by Shigehiro Tsukahara in
Google Scholar
PubMed
Search for other papers by Shohei Nagakawa in
Google Scholar
PubMed
Search for other papers by Takashi Matsumoto in
Google Scholar
PubMed
Search for other papers by Masatoshi Eto in
Google Scholar
PubMed
patients. Actually, recent analysis by liquid biopsy demonstrated that co-occurrence of AR mutation and amplification was observed in 5 (33.3%) among 15 clinical CRPC patients with AR mutation, in addition to co-occurrence with other genomic alterations
Search for other papers by Kristina Warton in
Google Scholar
PubMed
Garvan Institute of Medical Research, Chris O'Brien Lifehouse, The Kinghorn Cancer Centre and St Vincent's Clinical School, 370 Victoria Street, Darlinghurst, Sydeny, New South Wales, Australia
Search for other papers by Kate L Mahon in
Google Scholar
PubMed
Search for other papers by Goli Samimi in
Google Scholar
PubMed
limitations to obtaining sequence information from solid cancers: due to the clonal evolution and heterogeneity of a tumor, a single biopsy may not represent the diversity of DNA changes present; metastasized disease may be difficult to identify and access
Search for other papers by Karin Jennbacken in
Google Scholar
PubMed
Search for other papers by Tajana Tešan in
Google Scholar
PubMed
Search for other papers by Wanzhong Wang in
Google Scholar
PubMed
Search for other papers by Heléne Gustavsson in
Google Scholar
PubMed
Search for other papers by Jan-Erik Damber in
Google Scholar
PubMed
Search for other papers by Karin Welén in
Google Scholar
PubMed
to cell injection via the abdominal incision. The animal experiments were discontinued after 9 weeks. Tumors were harvested, and one part was fixed in formalin for paraffin embedding and the other part was frozen in liquid nitrogen and stored at −80
Search for other papers by Vera Cappelletti in
Google Scholar
PubMed
Search for other papers by Luigi Celio in
Google Scholar
PubMed
Search for other papers by Emilio Bajetta in
Google Scholar
PubMed
Search for other papers by Arianna Allevi in
Google Scholar
PubMed
Search for other papers by Raffaella Longarini in
Google Scholar
PubMed
Search for other papers by Patrizia Miodini in
Google Scholar
PubMed
Search for other papers by Raffaella Villa in
Google Scholar
PubMed
Search for other papers by Alessandra Fabbri in
Google Scholar
PubMed
Search for other papers by Luigi Mariani in
Google Scholar
PubMed
Search for other papers by Riccardo Giovanazzi in
Google Scholar
PubMed
Search for other papers by Emanuele Galante in
Google Scholar
PubMed
Search for other papers by Marco Greco in
Google Scholar
PubMed
Search for other papers by Maria Grazia Daidone in
Google Scholar
PubMed
(T2, T3, N0-1, M0) or locally advanced disease (T4b, N0-1, M0) entered the study. Tumor specimens for diagnosis and immunohistochemical assessment (ER-α, PgR) or molecular determinations (ER-β and ER-α mRNA) were obtained by 3–4 core needle biopsies
Search for other papers by C J Fabian in
Google Scholar
PubMed
Search for other papers by B F Kimler in
Google Scholar
PubMed
Search for other papers by M S Mayo in
Google Scholar
PubMed
Search for other papers by S A Khan in
Google Scholar
PubMed
have previously had a biopsy exhibiting atypical ductal hyperplasia (ADH), ductal or lobular carcinoma in situ (DCIS, LCIS), or currently have an estimated 5-year Gail model risk of >1.67% ( Fisher et al. 1998 , Cuzick et al. 2002 , Hershman et